Tissue-Type Plasminogen Activator (tPA) Content in Colorectal Cancer and in Surrounding Mucosa: Relationship with Clinicopathologic Parameters and Prognostic Significance
Free accessResearch articleFirst published online January, 2000
Tissue-Type Plasminogen Activator (tPA) Content in Colorectal Cancer and in Surrounding Mucosa: Relationship with Clinicopathologic Parameters and Prognostic Significance
The aim of this study was to evaluate the cytosolic tissue-type plasminogen activator (tPA) content in colorectal cancer, its possible relationship with the clinicopathologic parameters of tumors, and its prognostic significance. We have therefore examined by immunoenzymatic assay the cytosolic tPA content in tumors and paired surrounding normal mucosa samples from 162 colorectal cancer patients. Cytosolic tPA levels were significantly higher in surrounding normal mucosa samples than in neoplastic tissues (4.01±5.07 vs 2.63±5.82 ng/mg protein; p<0.0001). By contrast, no significant correlation was found between tPA content and clinicopathologic tumor parameters such as location, Dukes’ stage, histologic grade, and DNA content or S-phase fraction. However, the results indicated that a high cytosolic tPA content (>0.75 ng/mg protein) in tumors predicted for a shorter relapse-free and overall survival (both p<0.05) in 123 resectable colorectal cancer patients who were prospectively evaluated during a mean follow-up period of 32.2 months. This suggests that tPA may give additional information to that provided by other biochemical markers currently used in colorectal cancer.
BlackR.J., BrayF., FerlayJ., ParkinD.M.Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990.Eur J Cancer1997; 33: 1075–107.
2.
GreenwaldP.Colon cancer overview.Cancer1992; 70: 1206–15.
3.
GattaG., FaivreJ., CapocacciaR., Ponz de LeonM. the EUROCARE Working Group. Survival of colorectal cancer patients in Europe during the period 1978–1989.Eur J Cancer1998; 34: 2176–83.
4.
LiottaL.A., ThorgeirssonU.P., GarbisaS.Role of collagenases in tumor cell invasion, tissue degradation, and cancer.Cancer Metastasis Rev1982; 1: 277–97.
5.
MignattiP., RifkinD.B.Biology and biochemistry of proteinases in tumor invasion.Physiol Rev1993; 73: 161–95.
6.
DanöK., AndreasenP.A., Grondahl-HansenJ., KristensenP., NielsenL.S., SkriverL.Plasminogen activators, tissue degradation and cancer.Adv Cancer Res1985; 44: 139–266.
SierC.F.M., VerspagetH.W., GriffioenG.lmbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implication of urokinase in colorectal carcinogenesis.Gastroenterology1991; 101: 1522–8.
9.
TanakaN., FukaoH., UeshimaS., OkadaK., YasutomiM., MatsuoO.Plasminogen activator inhibitor in human carcinoma tissues.Int J Cancer1991; 48: 481–4.
10.
NakamuraM., KonnoH., TanakaT.Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues.Thromb Res1992; 65: 709–19.
11.
De VriesT.J., QuaxP.H.A., DenijnM.Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.Am J Pathol1994; 144: 70–81.
12.
JänickeF., SchmittM., HafterR.Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer.Fibrinolysis1990; 4: 69–78.
13.
FoekensJ.A., SchmittM., van PuttenW.L.J.Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.Cancer Res1992; 52: 6101–5.
14.
DuffyM.J., ReillyD., NolanN., O'HigginsN., FennellyJ.J., AndreasenP.Urokinase plasminogen activator, a strong and independent prognostic marker in breast cancer.Fibrinolysis1992; 6: 55–7.
15.
Gröndahl-HansenJ., ChristensenI.J., RosenquistC.High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.Cancer Res1993; 53: 2513–21.
16.
De WitteJ.H., SweepC.G.J., KlijnJ.G.M.Prognostic value of tissue-type plasminogen activator (tPA) and its complex with type-1 inhibitor (PAI-1) in breast cancer.Br J Cancer1999; 80: 286–94.
17.
JahkolaT., ToivonenT., von SmittenK.Cathepsin D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.Br J Cancer1999; 80: 167–74.
18.
PedersenH., BrunnerN., FrancisD.Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.Cancer Res1994; 54: 4671–5.
19.
NekardaH., SchmittM., UlmK.Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.Cancer Res1994; 54: 2900–7.
20.
HasuiY., MarutsukaK., SuzumiyaJ., KitadaS., OsadaY., SumiyoshiA.The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer.Int J Cancer1992; 50: 871–3.
21.
DuffyM.J., O'GradyP., SimonJ., RoseM., LijnenH.R.Tissue-type plasminogen activator in breast cancer: relationship with estradiol and progesterone receptors.J Natl Cancer Inst1986; 77: 621–3.
22.
JänickeF., SchmittM., GraeffH.Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type-1 inhibitor in breast cancer.Semin Thromb Hemost1991; 17: 303–12.
23.
De BruinP.A.F., GriffioenG., VerspagetH.W., VerheijenJ.H., LamersCBHW. Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.Cancer Res1987; 46: 4654–7.
24.
VerspagetH.W., SierC.F.M., GaneshS., GriffioenG., LamersCBHW. Prognostic value of plasminogen activators and their inhibitors in colorectal cancer.Eur J Cancer1995; 31A: 1105–9.
25.
GaneshS., SierC.F.M., GriffioenG.Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.Cancer Res1994; 54: 4065–75.
26.
MulcahyH.E., DuffyM.J., GibbonsD.Urokinase-type plasminogen activator and outcome in Dukes’ B colorectal cancer.Lancet1994; 344: 583–4.
27.
GaneshS., SierC.F.M., HeerdingM.M.Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes’ stage B and C colorectal cancer.Br J Cancer1997; 75: 1793–801.
28.
DukesC.E.The classification of cancer of the rectum.J Path Pract1932; 35: 323–32.
29.
BrodersA.C.The grading of carcinoma.Minn Med1925; 8: 726.
BradfordM.M.A rapid and sensitive method for the quantitation of microgram quantites of protein utilizing the principle of protein-dye binding.Anal Biochem1976; 72: 248–54.
33.
DixonW.J., BrownM.B., EngelmanL.BMDP statistical sofware.Berkeley: University of California Press, 1985.
34.
OssowskiL., Russo-PayneH., WilsonE.L.Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse.Cancer Res1991; 51: 274–81.
35.
CrowleyC.W., CohenR.L., LucasB.K., LiuG., ShumanM.A., LevinsonA.D.Prevention of metastasis by inhibition of the urokinase receptor.Proc Natl Acad Sci1994 USA; 90: 5021–5.
